SYS-CON MEDIA Authors: Yeshim Deniz, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Medtronic Announces Canadian Launch of Miniature Cardiac Monitor, Reveal LINQ(TM) ICM

Small, Wireless Monitor Provides Long-Term Remote Monitoring to Help Physicians Diagnose and Monitor Irregular Heartbeats

BRAMPTON, ON--(Marketwired - May 13, 2014) - Medtronic of Canada today announced it has received Health Canada license for the Reveal LINQ Insertable Cardiac Monitor (ICM), the smallest implantable cardiac monitoring device available for patients with irregular heartbeats, unexplained syncope (fainting), or unexplained stroke. 

The Reveal LINQ ICM is approximately one-third the size of an AAA battery (~1 cc), making it more than 80 percent smaller than other ICMs. While significantly smaller, the device is part of a powerful system that allows physicians to continuously and wirelessly monitor a patient's heart for up to three years, with 20 percent more data memory than its larger predecessors, Reveal® XT and DX. 

In addition to its continuous and wireless monitoring capabilities, the system provides remote monitoring through the CareLink® Network, which notifies physicians if patients have significant cardiac events between regular medical appointments. The Reveal LINQ ICM is indicated for patients with clinical syndromes or situations at increased risk of cardiac arrhythmias, such as atrial fibrillation, and for patients who experience transient symptoms that may suggest a cardiac arrhythmia. 

While Reveal LINQ can monitor for palpitations or syncope episodes, it also helps doctors determine if patients suffer from atrial fibrillation, which can appear intermittently and without symptoms. Atrial fibrillation, the most common heart rhythm disorder, is a major cause of stroke but is difficult to detect.1

Placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest, the Reveal LINQ ICM is often nearly invisible to the naked eye once inserted. The device is placed using a minimally invasive insertion procedure, which simplifies the experience for both physicians and their patients. The Reveal LINQ ICM is MR-Conditional, allowing patients, under certain conditions, to undergo magnetic resonance imaging (MRI) if needed.

"The first insertable cardiac monitor was invented by Dr. George Klein, Professor of Medicine, at Western University in London, Ontario. This Canadian invention was commercially developed as the Reveal™ Insertable Cardiac Monitor by Medtronic, Inc. The new Reveal LINQ™ is the result of many years of ongoing development to reduce its size, while adding wireless telemetry, enhancing performance, and improving benefits for patients," said Neil D. Fraser, President of Medtronic of Canada. "This innovative technology provides significant benefits for patients who need cardiac monitoring, and we look forward to providing them with the most technologically advanced and minimally invasive approach possible."

The Reveal LINQ system also includes the new MyCareLink™ Patient Monitor, a simplified remote monitoring system with global cellular technology that transmits patients' cardiac device diagnostic data to their clinicians from nearly any location in the world.

Medtronic, in collaboration with leading clinicians, researchers and scientists worldwide, offers the broadest range of innovative medical therapies for cardiovascular disease and cardiac arrhythmias.

About Medtronic of Canada Ltd.
Medtronic of Canada Ltd. is a trusted Canadian leader delivering innovative health system solutions and advanced medical technologies to alleviate pain, restore health, and extend life in the areas of cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose, throat surgery. Medtronic is proud to employ more than 700 Canadians. Headquartered in Brampton, Ontario, Medtronic has regional offices in Vancouver and Montreal, including a manufacturing facility, Medtronic CryoCath, located in Pointe-Claire, Quebec.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.5052135/k.2C86/Heart_disease__Atrial_fibrillation.htm

Contact :
Melicent Lavers
Public Relations
(905) 460-3653

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.